NKF

Interim PROTECT data show nephroprotective potential of sparsentan

If finerenone isn't available, try spironolactone, said researcher

Consider adding a potassium binder to the mix, researcher suggests

Analysis looked at patients with stage 1-3 CKD from the MIRROR trial

Goal of 30% reduction in serum creatinine in the absence of full response or HRS reversal

Temporary vascular access, uncontrolled hypertension may be risk factors in this population

A round-up of noteworthy research from the NKF Spring Clinical Meetings

Significant UPCR reductions in just a few weeks in phase II study

Promising findings from prespecified renal analysis of the DIAMOND trial

Researchers pinpointed six clinical variables predictive of rapid decline to ESRD

Those with advanced-stage kidney disease had 28% higher risk of in-hospital death

More critically ill COVID patients developed CKD versus bacterial pneumonia patients

Other noteworthy research presented at the National Kidney Foundation's annual meeting

Rates of death, serious adverse events lower than seen in clinical trial program